Andrographolide - InnoBioscience

Drug Profile

Andrographolide - InnoBioscience

Alternative Names: IB AD; IB DMD; IB MS; IB-MS 14

Latest Information Update: 29 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator InnoBioscience
  • Developer InnoBioscience; Pontifical Catholic University of Chile; Universidad Austral de Chile
  • Class Antidementias; Antifibrotics; Naphthalenes; Small molecules
  • Mechanism of Action Beta catenin stimulants; Connective tissue growth factor inhibitors; Glycogen synthase kinase 3 beta inhibitors; NF kappa B kinase inhibitors; Wnt signalling pathway stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Multiple sclerosis
  • Preclinical Alzheimer's disease; Duchenne muscular dystrophy; Fibrosis

Most Recent Events

  • 29 Mar 2018 Phase II development for Multiple sclerosis is ongoing (InnoBiosciences pipeline, March 2018)
  • 29 Mar 2018 Andrographolide - InnoBioscience is available for licensing as of 29 Mar 2018. http://www.innobioscience.com
  • 29 Mar 2018 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top